What is REGN's current stock price?

As of now, REGN is trading at $700.33, with a daily change of +0.62%.

What are REGN stock strengths?

REGN strengths include Expands stock buyback program, Investors confidence is positive, Outperform the market, Earnings are forecast to grow, Upgraded on attractively valued, .

What are the risks associated with REGN stock?

REGN Key risk is its Low Risk Level, .

What is REGN next earnings date?

REGN next earnings report is scheduled for Apr 30, 2025.

What is REGN's current stock rating?

REGN's current stock rating is Hold.

Should I buy REGN stock right now?

Based on the current rating of Hold, it is advisable to consider Hold as your next step with REGN stock.

Is REGN a Strong Buy right now?

REGN's current stock rating is Hold, which indicates whether it is a Strong Buy, Buy, Hold, Sell, or Strong Sell.

What does a 'Strong Buy' rating mean for REGN?

A 'Strong Buy' rating for REGN indicates that analysts are highly confident in the stock's potential for future growth.

What does a 'Strong Sell' rating mean for REGN?

A 'Strong Sell' rating for REGN suggests that analysts anticipate the stock will decline significantly and may not be a good investment.

What factors influence REGN's stock rating?

REGN's stock rating is influenced by factors such as market trends, earnings reports, risk factors, and overall sentiment from analysts.

Regeneron Pharmaceuticals (REGN) Stock Analysis and Insights

LOGIN

Market Overview Trending Stocks Stock Screener Trade Ideas

Top Rated Most Active Strong Potential Positive Momentum Earnings Calendar

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist

REGN

Regeneron Pharmaceuticals

$700.33

+$4.31 | +0.62%

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Open

$ 697.93

MKT CAP

$ 76.96B

High

$ 704.08

VOL

$ 727.09K

Low

$ 693.07

AVG VOL

$ 960.53K

Chart

696.88

737.78

1015.67

965.21

1year

6month

3month

1month

REGN Latest Headlines +

Deadline Alert: Regeneron Pharmaceuticals Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit. reminds investors of the upcoming ) securities between On April 10 2024 the United States Department of Justice (DOJ) announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ the Company failed to report millions of dollars in discounts provided to drug distributors in the form of reimbursed cred

Today

Activity

Levi &. Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10 2025 in Regeneron Pharmaceuticals Inc. Lawsuit - REGN. NEW YORK Feb. 21 2025 /PRNewswire/ -- Levi & Korsinsky LLP notifies investors in Regeneron Pharmaceuticals Inc. (Regeneron or the Company) (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors...

Today

Activity

Potential

Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight. Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies |. DelveInsight According to DelveInsight'.s analysis the chronic spontaneous urticaria market is expected to increase due to an increase in disease prevalence complemented by a rise i

Thu Feb 20, 2025

Activity

Regeneron Pharmaceuticals Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit. LOS ANGELES Feb. 20 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Regeneron Pharmaceuticals Inc. (Regeneron or the Company) (NASDAQ: REGN). IF YOU SUFFERED A LOSS ON...

Thu Feb 20, 2025

Activity

Potential

Regeneron Pharmaceuticals Inc. (REGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit.

Thu Feb 20, 2025

Activity

Explore our REGN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored REGN Stock Strategies
Effective Risk Management

FIND US ON

Receive our REGN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

Ideas

Earnings

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

REGN

Regeneron Pharmaceuticals

$700.33

+$4.31 | +0.62%

Chart

696.88

737.78

1015.67

965.21

1year

6month

3month

1month

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of REGN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our REGN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

REGN Stock trends

REGN Stock performance

REGN Stock analysis

REGN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

REGN Stock Analysis for the Last 90 Days

REGN Risk Level

REGN Analysts Opinion

REGN Street Consensus

REGN Performance Sentiment

Technical Price Levels

REGN Financial Health

REGN Fair Price vs Current Price

Explore our REGN Stock insights

Receive our REGN Daily Alerts

REGN Stock Analysis for the Last 90 Days

REGN Street Consensus

Technical Price Levels

REGN Fair Price vs Current Price

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of REGN. We're here to help you make informed investment decisions today.

Receive our REGN Daily Alerts